These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 18235987)

  • 1. Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis.
    Kamal MA; Qu X; Yu QS; Tweedie D; Holloway HW; Li Y; Tan Y; Greig NH
    J Neural Transm (Vienna); 2008 Jun; 115(6):889-98. PubMed ID: 18235987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine.
    Kamal MA; Klein P; Luo W; Li Y; Holloway HW; Tweedie D; Greig NH
    Neurochem Res; 2008 May; 33(5):745-53. PubMed ID: 17985237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetic analysis of the inhibition of human butyrylcholinesterase with cymserine.
    Kamal MA; Al-Jafari AA; Yu QS; Greig NH
    Biochim Biophys Acta; 2006 Feb; 1760(2):200-6. PubMed ID: 16309845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Butyrylcholinesterase with Fluorobenzylcymserine, An Experimental Alzheimer's Drug Candidate: Validation of Enzoinformatics Results by Classical and Innovative Enzyme Kinetic Analyses.
    Kamal MA; Shakil S; Nawaz MS; Yu QS; Tweedie D; Tan Y; Qu X; Greig NH
    CNS Neurol Disord Drug Targets; 2017; 16(7):820-827. PubMed ID: 28176640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine.
    Kamal MA; Klein P; Yu QS; Tweedie D; Li Y; Holloway HW; Greig NH
    J Alzheimers Dis; 2006 Sep; 10(1):43-51. PubMed ID: 16988481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular interaction study of N1-p-fluorobenzyl-cymserine with TNF-α , p38 kinase and JNK kinase.
    Batool S; Nawaz MS; Greig NH; Rehan M; Kamal MA
    Antiinflamm Antiallergy Agents Med Chem; 2013; 12(2):129-35. PubMed ID: 23360257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy.
    Greig NH; Lahiri DK; Sambamurti K
    Int Psychogeriatr; 2002; 14 Suppl 1():77-91. PubMed ID: 12636181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase.
    Greig NH; Utsuki T; Yu Q; Zhu X; Holloway HW; Perry T; Lee B; Ingram DK; Lahiri DK
    Curr Med Res Opin; 2001; 17(3):159-65. PubMed ID: 11900310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus.
    Mushtaq G; Greig NH; Khan JA; Kamal MA
    CNS Neurol Disord Drug Targets; 2014; 13(8):1432-9. PubMed ID: 25345511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting acetylcholinesterase and butyrylcholinesterase in dementia.
    Lane RM; Potkin SG; Enz A
    Int J Neuropsychopharmacol; 2006 Feb; 9(1):101-24. PubMed ID: 16083515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease.
    Yu Q; Holloway HW; Utsuki T; Brossi A; Greig NH
    J Med Chem; 1999 May; 42(10):1855-61. PubMed ID: 10346939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease?
    Giacobini E
    Drugs Aging; 2001; 18(12):891-8. PubMed ID: 11888344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses.
    Kuhl DE; Koeppe RA; Snyder SE; Minoshima S; Frey KA; Kilbourn MR
    Ann Neurol; 2006 Jan; 59(1):13-20. PubMed ID: 16278840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
    Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR
    J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholinesterases: new roles in brain function and in Alzheimer's disease.
    Giacobini E
    Neurochem Res; 2003 Apr; 28(3-4):515-22. PubMed ID: 12675140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain.
    Rakonczay Z
    Acta Biol Hung; 2003; 54(2):183-9. PubMed ID: 14535624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The interactions of azure B, a metabolite of methylene blue, with acetylcholinesterase and butyrylcholinesterase.
    Petzer A; Harvey BH; Petzer JP
    Toxicol Appl Pharmacol; 2014 Feb; 274(3):488-93. PubMed ID: 24161345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics.
    Greig NH; De Micheli E; Holloway HW; Yu QS; Utsuki T; Perry TA; Brossi A; Ingram DK; Deutsch J; Lahiri DK; Soncrant TT
    Acta Neurol Scand Suppl; 2000; 176():74-84. PubMed ID: 11261809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of heptyl-physostigmine, a new cholinesterase inhibitor, on the central cholinergic system of the rat.
    De Sarno P; Pomponi M; Giacobini E; Tang XC; Williams E
    Neurochem Res; 1989 Oct; 14(10):971-7. PubMed ID: 2608162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.
    Nordberg A; Ballard C; Bullock R; Darreh-Shori T; Somogyi M
    Prim Care Companion CNS Disord; 2013; 15(2):. PubMed ID: 23930233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.